Drug-Induced Myopathy / Rhabdomyolysis – Decision Support Tool
Drug-Induced Myopathy / Rhabdomyolysis – Decision Support
Screen • Timing • Labs • Severity • Likelihood • Causality • Differentials • Management • PV Reporting • Summary
1) Patient & Exposure
Risk factors
2) Symptoms & Signs
3) Labs
4) Timing – TTO
Fill dates above to auto-calculate. Interpretation depends on drug class (see “Risk window fit” on the right).
5) Pattern & Severity (auto)
Pattern
–
Severity tier
–
Based on CK, AKI, electrolytes.
Risk window fit
–
Action: Stop suspect drug; check CK, electrolytes, renal function; begin fluids if rhabdomyolysis suspected.
6) Rhabdomyolysis Likelihood – Quick Score (0–10)
ADR likelihood: –
Add inputs to compute.
0/10
7) Causality Assessment
WHO-UMC helper
WHO-UMC category: —
This is a rule-of-thumb mapping for bedside use.
Advanced: Naranjo mini-calculator
Naranjo score: 0
Category: —
Definite ≥9 • Probable 5–8 • Possible 1–4 • Doubtful ≤0
8) Alternatives considered
9) Management – Smart Suggestions
10) Case Summary
For decision support; follow local protocols/consult specialists for emergencies.
11) Pharmacovigilance (Regulatory Reporting)
Seriousness (select all that apply)
Seriousness result
—
Select criteria above. Auto-suggests based on severity.
Expedited rule
—
Based on role, region, expectedness, trial.
Report due
—
Uses awareness date + timeline.
Routing/Channel: —
Minimum case info (E2B(R3) “four min”): identifiable patient, identifiable reporter, suspect product, adverse event. Add dates, dose, outcome, labs, dechallenge, relevant history.
What gets expedited where?
- USA (FDA), MAH:
15 daysfor serious & unexpected ICSRs (postmarketing). Others go to periodic reports (PADER/PSUR) per requirements. - EU/EEA (EMA), MAH:
15 daysfor all serious ICSRs;90 daysfor non-serious → EudraVigilance. - UK (MHRA), MAH: mirrors EU: serious
15 days; non-serious90 days→ MHRA Gateway/ICH E2B(R3). - Canada (Health Canada), MAH:
15 daysfor serious ADRs (expectedness not required); non-serious to periodic/aggregate. - Australia (TGA), sponsor: Serious
15 days; non-serious90 daysfor medicines. - Clinical trials (SUSAR), sponsor: Fatal/life-threatening
7 days(+8-day follow-up); other SUSARs15 daysto regulators/ethics (per ICH E2A/EU CTR/local law). - HCP/Patient: Report as soon as possible via national portals (e.g., FDA MedWatch, MHRA Yellow Card).
